17 clinical trials found.
-
A PHASE 1B/2A MULTICENTER OPEN-LABEL DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
The purpose of this study is to test the safety and to define the appropriate dose of an investigational drug (CC-220) and an investigational combination ... -
Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy system in Patients with Post Myocardial Infarction Heart Failure (CardiAMP Heart Failure Trial)
The purpose of this study is to evaluate the CardiAMP cell therapy system as a treatment for patients with heart failure as a result of ... -
AN OPEN-LABEL RANDOMIZED MULTICENTER PHASE Ib/II TRIAL EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA
The purpose of this study is to test the safety of mosunetuzumab at different dose levels when given in combination with polatuzumab vedotin and to ... -
CDA Diefenbach Medpace Protocol ID ME-522-001 titled: A Phase 1 Open-label Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies After Failure of Prior Standard Therapies
If you have been diagnosed with a B cell type cancer that has relapsed (come back) or is refractory (did not respond to previous treatment ... -
A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations
If you have been diagnosed with intermediate or high risk Myelodysplastic Syndrome with a mutation in the Tet methylcytosine dioxygenase (abbreviated as TET) gene, you ... -
AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
If you have been diagnosed with non-Hodgkin s lymphoma (NHL) or chronic lymphocytic leukemia (CLL) that relapsed after previous treatment(s), did not respond to ... -
A Phase 1 Study with an Expansion Cohort/Randomized Phase II Study of the Combination of Ipilimumab Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
If you have been newly diagnosed with relapsed/refractory Hodgkin lymphoma and are exploring treatment options, you may qualify for a clinical trial studying effect ...
-
A Phase 1 Study of TJ011133 Administered Alone or in Combination with Pembrolizumab or Rituximab in Subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma
The purpose of this study is to test the safety of a study drug called TJ011133 alone, and to test the safety of TJ011133 in ... -
A Three-Arm Study of ME-401 Monotherapy in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL) of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell Non-Hodgkin s Lymphoma (NHL) and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL
The purpose of this study is to look at how your body tolerates ME-401, how effective ME-401 may be, and how ME-401 is taken up ... -
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
The current study is being conducted to evaluate the MRD negativity conversion rate following the addition of daratumumab to lenalidomide, when administered as maintenance treatment ...
